ZIOPHARM Oncology CEO Kevin Boyle's 2022 pay falls 61% to $1.8M
ZIOPHARM Oncology reports 2022 executive compensation
By ExecPay News
Published: April 25, 2023
ZIOPHARM Oncology reported fiscal year 2022 executive compensation information on April 25, 2023.
In 2022, three executives at ZIOPHARM Oncology received on average a compensation package of $1.2M, a 74% decrease compared to previous year.
Average pay of disclosed executives at ZIOPHARM Oncology
Kevin S. Boyle, Sr, Chief Executive Officer, received $1.8M in total, which decreased by 61% compared to 2021. 50% of Boyle's compensation, or $904K, was in option awards. Boyle also received $270K in bonus, $600K in salary, as well as $19K in other compensation.
Drew Deniger, VP, Research and Development, received a compensation package of $949K. 51% of the compensation package, or $481K, was in option awards.
Melinda Lackey, SVP, Legal & Administration, earned $765K in 2022.
Related executives
You may also like
Source: SEC filing on April 25, 2023.